Aurinia Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount
Aurinia Pharmaceuticals Inc. (AUPH) reported Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount of $152.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherReconcilingItems · last filed 2026-02-26
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2024 was $152.00K, a 1.30% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2023 was $154.00K, a 87.17% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other reconciling items, amount for fiscal 2022 was $1.20M.
| Period end | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount 12 month |
|---|---|
| 2024-12-31 | $152.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $154.00K 10-K · filed 2026-02-26 |
| 2022-12-31 | $1.20M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |